心悅生醫 | 美體產業公開資訊

關於我們·公司簡介·公司願景·組織架構;領導團隊.董事會·經營團隊·公司沿革·新藥產品研發;臨床試驗.SchizophreniaTrials·DementiaTrials·Depression ...

We intend to move forward with our human-health focus, leaning towards mental health parity through developing potential treatments for schizophrenia, dementia, and depression.[1]

In terms of COVID-19, I see us addressing this pandemic through a variety of tools, be it traditional Chinese medicines, FDA-approved chemical drugs, or regional-dependent health supplements.

As we forge ahead, we want to always meet these important health issues head on and with an efficient development process. Our goal is to bypass, when it is scientifically sound to do so, the sometimes decade-long delay or billion dollar cost chasm to develop new therapies.